Edwards’ Hemodynamic Monitoring Platform Nabs FDA Clearance

April 19, 2017

California–based Edwards Lifesciences Corp. has received FDA clearance for its HemoSphere advanced monitoring platform.

The device monitor provides clinicians with more information on a patient’s hemodynamics, the factors that manage blood flow, to help them make clinical decisions.

The product is compatible with the company’s Swan-Ganz pulmonary artery catheter and oximetry catheters.

The device is also approved for commercial use in Europe, Japan, Australia and New Zealand. — Cynthia Jessup

View today's stories